Under the Fourth Agreement Dose Administration Aids (DAA) Program, pharmacies provided information and data on the DAA services they were providing to their patients.
The data collected from the DAA Program was used in the efforts to inform possible future arrangements for services provided through the community pharmacy setting. This has resulted in the provision of DAAs being included under the Pharmacy Practice Incentives Program (PPI) in the Fifth Community Pharmacy Agreement. In addition, the data obtained from the Patient Medication Profiles (PMP) Program will inform the development of the MedsCheck Program which may include the provision of PMPs.
This shows that there is a clear linkage between quality research and the successful implementation of professional services.
The following are some results from the data provided by pharmacies who participated in the DAA and/or PMP programs:
In Phase 2, the majority of patients who received a DAA were taking between three to six (76%) medications. The majority of patients were taking blood pressure medications (83.7%) and lipids (62.5%). Most patients in both Phase 1 and Phase 2 were aged 75 or older and approximately 60% of patients were female.
In Phase 1, 49.7% of patients were receiving a DAA only. Approximately 43.4% of patients were receiving one other pharmacy service and around 7% were receiving two or more other services. Of those receiving another service, 42.8% were receiving a PMP and 13.8% a HMR. At the end of Phase 2, the percentage of patients receiving a DAA only had increased to 60.3%.
Although the DAA Program under the Fourth Community Pharmacy Agreement has finished, many pharmacies of all types and sizes continue provide DAA services to their patients.